Slingshot Insights

Catalyst

Slingshot members are tracking this event:

New Clinical and Preclinical Data to be Presented at AACR Annual Meeting

Source Link:: http://ir.celldex.com/releasedetail.cfm?ReleaseID=961239

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

CLDX

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.

http://ir.celldex.co...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Apr 20, 2016

Occurred Source:

http://ir.celldex.com/releasedetail.cfm?ReleaseID=965948

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Clinical Data, Preclinical Data Abstract, Phase 1/2 Data, Varlilumab, Nivolumab, Gpnmb, Cdx-301